Clinical Trial Update: Surufatinib Combined With Sintilimab and AG in First-line Therapy of Patients With Locally Advanced or Metastatic Pancreatic Cancer [Phase 2]

View source ↗

Summary

Clinical trial update on first-line therapy for locally advanced or metastatic pancreatic cancer using surufatinib in combination with sintilimab and AG in a Ph…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• AG
• Sintilimab (Tyvyt) (sintilimab)
• Surufatinib (Surufatinib)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Pancreatic Neoplasms | Phase 2 | Status: ACTIVE_NOT_RECRUITING